EA030195B1 - Макроциклические ингибиторы белок/белковых взаимодействий pd-1/pd-l1 и cd80(b7-1)/pd-l1 - Google Patents

Info

Publication number

EA030195B1

EA030195B1 EA201591822A EA201591822A EA030195B1 EA 030195 B1 EA030195 B1 EA 030195B1 EA 201591822 A EA201591822 A EA 201591822A EA 201591822 A EA201591822 A EA 201591822A EA 030195 B1 EA030195 B1 EA 030195B1

Authority

EA

Eurasian Patent Office

Prior art keywords

alkyl

optionally substituted

methyl

halogen

group

Prior art date

2013-03-15

Links

• Espacenet
• Global Dossier
• Discuss

• 230000006916 protein interaction Effects 0.000 title abstract description 4
• 102000008096 B7-H1 Antigen Human genes 0.000 title abstract 3
• 108010074708 B7-H1 Antigen Proteins 0.000 title abstract 3
• 239000003112 inhibitor Substances 0.000 title description 5
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 108
• 150000001875 compounds Chemical class 0.000 claims abstract description 100
• 201000011510 cancer Diseases 0.000 claims abstract description 54
• 208000035473 Communicable disease Diseases 0.000 claims abstract description 13
• 238000000034 method Methods 0.000 claims description 225
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 132
• 235000001014 amino acid Nutrition 0.000 claims description 117
• 229940024606 amino acid Drugs 0.000 claims description 116
• 150000001413 amino acids Chemical class 0.000 claims description 115
• -1 furanylcarbonyl Chemical group 0.000 claims description 112
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 81
• 229910052736 halogen Inorganic materials 0.000 claims description 54
• 150000002367 halogens Chemical class 0.000 claims description 52
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 51
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 46
• 229910052739 hydrogen Inorganic materials 0.000 claims description 46
• 239000001257 hydrogen Substances 0.000 claims description 46
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 42
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 42
• 125000004429 atom Chemical group 0.000 claims description 38
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
• 230000028993 immune response Effects 0.000 claims description 31
• 150000003839 salts Chemical class 0.000 claims description 29
• 230000003993 interaction Effects 0.000 claims description 28
• 229910052700 potassium Inorganic materials 0.000 claims description 27
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
• HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 23
• OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims description 21
• 230000002401 inhibitory effect Effects 0.000 claims description 19
• 241000700605 Viruses Species 0.000 claims description 18
• 229910052757 nitrogen Inorganic materials 0.000 claims description 18
• 208000015181 infectious disease Diseases 0.000 claims description 17
• 230000003211 malignant effect Effects 0.000 claims description 17
• 150000002431 hydrogen Chemical class 0.000 claims description 16
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 15
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
• 229910052799 carbon Inorganic materials 0.000 claims description 13
• 125000001041 indolyl group Chemical group 0.000 claims description 13
• 201000001441 melanoma Diseases 0.000 claims description 13
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
• 125000003368 amide group Chemical group 0.000 claims description 10
• 230000000903 blocking effect Effects 0.000 claims description 10
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 10
• 230000012010 growth Effects 0.000 claims description 10
• 125000005843 halogen group Chemical group 0.000 claims description 10
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 9
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
• 125000003342 alkenyl group Chemical group 0.000 claims description 8
• 125000004970 halomethyl group Chemical group 0.000 claims description 8
• 229960004441 tyrosine Drugs 0.000 claims description 8
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 8
• 235000002374 tyrosine Nutrition 0.000 claims description 8
• 239000004471 Glycine Substances 0.000 claims description 7
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 7
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 7
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 7
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 7
• 239000004473 Threonine Substances 0.000 claims description 7
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 7
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 7
• 229960002433 cysteine Drugs 0.000 claims description 7
• 235000018417 cysteine Nutrition 0.000 claims description 7
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
• 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
• 230000002708 enhancing effect Effects 0.000 claims description 7
• 229960002449 glycine Drugs 0.000 claims description 7
• 229960002885 histidine Drugs 0.000 claims description 7
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
• 229960000310 isoleucine Drugs 0.000 claims description 7
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
• 229960002898 threonine Drugs 0.000 claims description 7
• 235000008521 threonine Nutrition 0.000 claims description 7
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
• 229960004799 tryptophan Drugs 0.000 claims description 7
• 229960004295 valine Drugs 0.000 claims description 7
• 239000004474 valine Substances 0.000 claims description 7
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
• 239000004475 Arginine Substances 0.000 claims description 6
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 6
• 206010009944 Colon cancer Diseases 0.000 claims description 6
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 6
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 6
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 6
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
• 239000004472 Lysine Substances 0.000 claims description 6
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
• 229960003767 alanine Drugs 0.000 claims description 6
• 235000004279 alanine Nutrition 0.000 claims description 6
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 6
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
• 229960003121 arginine Drugs 0.000 claims description 6
• 235000009697 arginine Nutrition 0.000 claims description 6
• 229960001230 asparagine Drugs 0.000 claims description 6
• 235000009582 asparagine Nutrition 0.000 claims description 6
• 229960005261 aspartic acid Drugs 0.000 claims description 6
• 235000003704 aspartic acid Nutrition 0.000 claims description 6
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 6
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
• 229960002989 glutamic acid Drugs 0.000 claims description 6
• 235000013922 glutamic acid Nutrition 0.000 claims description 6
• 239000004220 glutamic acid Substances 0.000 claims description 6
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
• 235000004554 glutamine Nutrition 0.000 claims description 6
• 229960002743 glutamine Drugs 0.000 claims description 6
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
• 229960003136 leucine Drugs 0.000 claims description 6
• 229960003646 lysine Drugs 0.000 claims description 6
• 229930182817 methionine Natural products 0.000 claims description 6
• 229960004452 methionine Drugs 0.000 claims description 6
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
• 229960005190 phenylalanine Drugs 0.000 claims description 6
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
• 230000035755 proliferation Effects 0.000 claims description 6
• 229960002429 proline Drugs 0.000 claims description 6
• 229960001153 serine Drugs 0.000 claims description 6
• 235000004400 serine Nutrition 0.000 claims description 6
• 206010040070 Septic Shock Diseases 0.000 claims description 5
• 235000010290 biphenyl Nutrition 0.000 claims description 5
• 239000004305 biphenyl Substances 0.000 claims description 5
• 230000036303 septic shock Effects 0.000 claims description 5
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 5
• 241001529453 unidentified herpesvirus Species 0.000 claims description 5
• 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 4
• 206010060862 Prostate cancer Diseases 0.000 claims description 4
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
• 125000003386 piperidinyl group Chemical group 0.000 claims description 4
• 230000004936 stimulating effect Effects 0.000 claims description 4
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
• 206010027476 Metastases Diseases 0.000 claims description 3
• 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
• 206010022000 influenza Diseases 0.000 claims description 3
• 230000009401 metastasis Effects 0.000 claims description 3
• 208000005176 Hepatitis C Diseases 0.000 claims description 2
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 2
• 125000001153 fluoro group Chemical group F* 0.000 claims description 2
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
• 208000005252 hepatitis A Diseases 0.000 claims description 2
• 208000002672 hepatitis B Diseases 0.000 claims description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
• 210000002307 prostate Anatomy 0.000 claims description 2
• 210000002784 stomach Anatomy 0.000 claims description 2
• 125000004356 hydroxy functional group Chemical group O* 0.000 claims 16
• 206010041067 Small cell lung cancer Diseases 0.000 claims 2
• 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
• 210000004907 gland Anatomy 0.000 claims 1
• 230000002489 hematologic effect Effects 0.000 claims 1
• 235000013336 milk Nutrition 0.000 claims 1
• 210000004080 milk Anatomy 0.000 claims 1
• 239000008267 milk Substances 0.000 claims 1
• 108090000765 processed proteins & peptides Proteins 0.000 abstract description 296
• 102000004196 processed proteins & peptides Human genes 0.000 abstract description 143
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 45
• 201000010099 disease Diseases 0.000 abstract description 36
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 1
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 1
• ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 367
• 239000000243 solution Substances 0.000 description 278
• 239000000203 mixture Substances 0.000 description 266
• 229920005989 resin Polymers 0.000 description 262
• 239000011347 resin Substances 0.000 description 262
• 238000006243 chemical reaction Methods 0.000 description 179
• 239000000427 antigen Substances 0.000 description 92
• 108091007433 antigens Proteins 0.000 description 92
• 102000036639 antigens Human genes 0.000 description 92
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 87
• 238000005406 washing Methods 0.000 description 85
• 230000027455 binding Effects 0.000 description 62
• 238000009739 binding Methods 0.000 description 60
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 57
• 210000004027 cell Anatomy 0.000 description 55
• 238000007792 addition Methods 0.000 description 50
• 238000011282 treatment Methods 0.000 description 41
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 39
• 210000001744 T-lymphocyte Anatomy 0.000 description 38
• 239000007787 solid Substances 0.000 description 38
• 108090000623 proteins and genes Proteins 0.000 description 36
• 241000282414 Homo sapiens Species 0.000 description 35
• 239000012071 phase Substances 0.000 description 35
• 238000004458 analytical method Methods 0.000 description 34
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
• 125000000217 alkyl group Chemical group 0.000 description 31
• 235000018102 proteins Nutrition 0.000 description 31
• 102000004169 proteins and genes Human genes 0.000 description 31
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 30
• 125000003118 aryl group Chemical group 0.000 description 28
• 239000003795 chemical substances by application Substances 0.000 description 27
• 230000008569 process Effects 0.000 description 27
• 238000010511 deprotection reaction Methods 0.000 description 26
• 230000008961 swelling Effects 0.000 description 26
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 25
• 235000002639 sodium chloride Nutrition 0.000 description 25
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 24
• 239000003814 drug Substances 0.000 description 24
• 230000001225 therapeutic effect Effects 0.000 description 24
• 210000004881 tumor cell Anatomy 0.000 description 24
• 230000015572 biosynthetic process Effects 0.000 description 21
• 125000005647 linker group Chemical group 0.000 description 21
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 21
• 230000005587 bubbling Effects 0.000 description 20
• 239000004480 active ingredient Substances 0.000 description 19
• 125000003275 alpha amino acid group Chemical group 0.000 description 19
• 230000000694 effects Effects 0.000 description 19
• 150000003335 secondary amines Chemical class 0.000 description 19
• 239000002904 solvent Substances 0.000 description 19
• 239000006228 supernatant Substances 0.000 description 19
• 238000003786 synthesis reaction Methods 0.000 description 19
• 239000003153 chemical reaction reagent Substances 0.000 description 17
• 238000002360 preparation method Methods 0.000 description 17
• 239000000725 suspension Substances 0.000 description 17
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 16
• 238000002474 experimental method Methods 0.000 description 16
• 241000725303 Human immunodeficiency virus Species 0.000 description 15
• 125000004432 carbon atom Chemical group C* 0.000 description 15
• 230000001965 increasing effect Effects 0.000 description 15
• 238000005304 joining Methods 0.000 description 15
• 230000004044 response Effects 0.000 description 15
• 239000004743 Polypropylene Substances 0.000 description 14
• 239000008194 pharmaceutical composition Substances 0.000 description 14
• 229920001155 polypropylene Polymers 0.000 description 14
• 238000001514 detection method Methods 0.000 description 13
• 229940079593 drug Drugs 0.000 description 13
• 229920000642 polymer Polymers 0.000 description 13
• 238000002255 vaccination Methods 0.000 description 13
• 229920001184 polypeptide Polymers 0.000 description 12
• 229960005486 vaccine Drugs 0.000 description 12
• 230000037396 body weight Effects 0.000 description 11
• 239000003937 drug carrier Substances 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• 208000024891 symptom Diseases 0.000 description 11
• VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 10
• 125000001072 heteroaryl group Chemical group 0.000 description 10
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
• 244000052769 pathogen Species 0.000 description 10
• 230000028327 secretion Effects 0.000 description 10
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
• 230000004913 activation Effects 0.000 description 9
• 238000012217 deletion Methods 0.000 description 9
• 230000037430 deletion Effects 0.000 description 9
• 208000035475 disorder Diseases 0.000 description 9
• 238000001802 infusion Methods 0.000 description 9
• 238000001990 intravenous administration Methods 0.000 description 9
• 238000002156 mixing Methods 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 150000003431 steroids Chemical class 0.000 description 9
• 229940124597 therapeutic agent Drugs 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 8
• 108090000695 Cytokines Proteins 0.000 description 8
• 241000701022 Cytomegalovirus Species 0.000 description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
• 241000282567 Macaca fascicularis Species 0.000 description 8
• 241000699666 Mus <mouse, genus> Species 0.000 description 8
• 239000004793 Polystyrene Substances 0.000 description 8
• 238000002648 combination therapy Methods 0.000 description 8
• 239000002552 dosage form Substances 0.000 description 8
• 230000006870 function Effects 0.000 description 8
• 230000014509 gene expression Effects 0.000 description 8
• 230000003463 hyperproliferative effect Effects 0.000 description 8
• 230000036039 immunity Effects 0.000 description 8
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
• 239000002245 particle Substances 0.000 description 8
• 229920002223 polystyrene Polymers 0.000 description 8
• 125000006239 protecting group Chemical group 0.000 description 8
• 238000010521 absorption reaction Methods 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 150000001408 amides Chemical class 0.000 description 7
• 125000000539 amino acid group Chemical group 0.000 description 7
• 239000002775 capsule Substances 0.000 description 7
• FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 7
• 230000001684 chronic effect Effects 0.000 description 7
• 125000000753 cycloalkyl group Chemical group 0.000 description 7
• 239000012634 fragment Substances 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• 239000002502 liposome Substances 0.000 description 7
• 238000011068 loading method Methods 0.000 description 7
• 238000004949 mass spectrometry Methods 0.000 description 7
• 125000004430 oxygen atom Chemical group O* 0.000 description 7
• 230000037361 pathway Effects 0.000 description 7
• 238000010647 peptide synthesis reaction Methods 0.000 description 7
• 229920005990 polystyrene resin Polymers 0.000 description 7
• 150000003141 primary amines Chemical class 0.000 description 7
• 238000007920 subcutaneous administration Methods 0.000 description 7
• ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 7
• 230000003612 virological effect Effects 0.000 description 7
• 229940045513 CTLA4 antagonist Drugs 0.000 description 6
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
• 125000003277 amino group Chemical group 0.000 description 6
• 239000003963 antioxidant agent Substances 0.000 description 6
• 235000006708 antioxidants Nutrition 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 230000000973 chemotherapeutic effect Effects 0.000 description 6
• 229940106681 chloroacetic acid Drugs 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 125000004122 cyclic group Chemical group 0.000 description 6
• 210000004443 dendritic cell Anatomy 0.000 description 6
• 238000012377 drug delivery Methods 0.000 description 6
• 238000011010 flushing procedure Methods 0.000 description 6
• 230000003308 immunostimulating effect Effects 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 125000001151 peptidyl group Chemical group 0.000 description 6
• 238000007363 ring formation reaction Methods 0.000 description 6
• 238000003746 solid phase reaction Methods 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 230000004614 tumor growth Effects 0.000 description 6
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 5
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 5
• 102000008203 CTLA-4 Antigen Human genes 0.000 description 5
• 241000283923 Marmota monax Species 0.000 description 5
• 241000699670 Mus sp. Species 0.000 description 5
• 208000037581 Persistent Infection Diseases 0.000 description 5
• 229920002472 Starch Polymers 0.000 description 5
• 210000000612 antigen-presenting cell Anatomy 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• 229960004436 budesonide Drugs 0.000 description 5
• 210000004899 c-terminal region Anatomy 0.000 description 5
• 230000034994 death Effects 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 239000006185 dispersion Substances 0.000 description 5
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
• 239000003862 glucocorticoid Substances 0.000 description 5
• 125000000623 heterocyclic group Chemical group 0.000 description 5
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
• 210000000987 immune system Anatomy 0.000 description 5
• 229940127121 immunoconjugate Drugs 0.000 description 5
• 230000002458 infectious effect Effects 0.000 description 5
• 238000007918 intramuscular administration Methods 0.000 description 5
• 150000002500 ions Chemical class 0.000 description 5
• 150000002678 macrocyclic compounds Chemical class 0.000 description 5
• 235000019359 magnesium stearate Nutrition 0.000 description 5
• 230000036210 malignancy Effects 0.000 description 5
• 239000011159 matrix material Substances 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 231100000252 nontoxic Toxicity 0.000 description 5
• 230000003000 nontoxic effect Effects 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 230000000069 prophylactic effect Effects 0.000 description 5
• 238000000159 protein binding assay Methods 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 239000008107 starch Substances 0.000 description 5
• 235000019698 starch Nutrition 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 238000013268 sustained release Methods 0.000 description 5
• 239000012730 sustained-release form Substances 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
• 239000005695 Ammonium acetate Substances 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 4
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 4
• 208000007766 Kaposi sarcoma Diseases 0.000 description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• 108010029485 Protein Isoforms Proteins 0.000 description 4
• 102000001708 Protein Isoforms Human genes 0.000 description 4
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
• 241000555745 Sciuridae Species 0.000 description 4
• 230000006044 T cell activation Effects 0.000 description 4
• 239000012190 activator Substances 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 230000002411 adverse Effects 0.000 description 4
• 125000003545 alkoxy group Chemical group 0.000 description 4
• 235000019257 ammonium acetate Nutrition 0.000 description 4
• 229940043376 ammonium acetate Drugs 0.000 description 4
• 230000006023 anti-tumor response Effects 0.000 description 4
• 230000030741 antigen processing and presentation Effects 0.000 description 4
• 125000003710 aryl alkyl group Chemical group 0.000 description 4
• 238000000889 atomisation Methods 0.000 description 4
• 210000003719 b-lymphocyte Anatomy 0.000 description 4
• 239000011575 calcium Substances 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 230000030833 cell death Effects 0.000 description 4
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
• 238000000576 coating method Methods 0.000 description 4
• 208000029742 colonic neoplasm Diseases 0.000 description 4
• 230000006378 damage Effects 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 235000019253 formic acid Nutrition 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 239000007903 gelatin capsule Substances 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 208000014829 head and neck neoplasm Diseases 0.000 description 4
• 208000006454 hepatitis Diseases 0.000 description 4
• 231100000283 hepatitis Toxicity 0.000 description 4
• 125000005842 heteroatom Chemical group 0.000 description 4
• 230000001900 immune effect Effects 0.000 description 4
• 230000003053 immunization Effects 0.000 description 4
• 238000002649 immunization Methods 0.000 description 4
• 230000002163 immunogen Effects 0.000 description 4
• 239000003018 immunosuppressive agent Substances 0.000 description 4
• 229940125721 immunosuppressive agent Drugs 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 239000008101 lactose Substances 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 239000000523 sample Substances 0.000 description 4
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
• 238000010532 solid phase synthesis reaction Methods 0.000 description 4
• 230000000392 somatic effect Effects 0.000 description 4
• 239000000600 sorbitol Substances 0.000 description 4
• 235000010356 sorbitol Nutrition 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 230000009870 specific binding Effects 0.000 description 4
• 150000008163 sugars Chemical class 0.000 description 4
• 229910052717 sulfur Inorganic materials 0.000 description 4
• 230000001629 suppression Effects 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• PNVPNXKRAUBJGW-UHFFFAOYSA-N (2-chloroacetyl) 2-chloroacetate Chemical compound ClCC(=O)OC(=O)CCl PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 description 3
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
• FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 3
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
• PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 3
• 208000037259 Amyloid Plaque Diseases 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
• 241000152447 Hades Species 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• 206010033128 Ovarian cancer Diseases 0.000 description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 description 3
• 108010004729 Phycoerythrin Proteins 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 229920000954 Polyglycolide Polymers 0.000 description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 208000002495 Uterine Neoplasms Diseases 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 3
• 125000000304 alkynyl group Chemical group 0.000 description 3
• 239000005557 antagonist Substances 0.000 description 3
• 230000001093 anti-cancer Effects 0.000 description 3
• 230000000259 anti-tumor effect Effects 0.000 description 3
• 230000005875 antibody response Effects 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• 230000005975 antitumor immune response Effects 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
• 125000005110 aryl thio group Chemical group 0.000 description 3
• 125000004104 aryloxy group Chemical group 0.000 description 3
• 230000001363 autoimmune Effects 0.000 description 3
• 230000006472 autoimmune response Effects 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 230000008499 blood brain barrier function Effects 0.000 description 3
• 210000001218 blood-brain barrier Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 3
• 238000011260 co-administration Methods 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 230000002860 competitive effect Effects 0.000 description 3
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 230000005714 functional activity Effects 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 125000002541 furyl group Chemical group 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 125000001188 haloalkyl group Chemical group 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 125000005553 heteroaryloxy group Chemical group 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 125000002883 imidazolyl group Chemical group 0.000 description 3
• 210000002865 immune cell Anatomy 0.000 description 3
• 238000009169 immunotherapy Methods 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 239000007972 injectable composition Substances 0.000 description 3
• 201000010982 kidney cancer Diseases 0.000 description 3
• 239000000787 lecithin Substances 0.000 description 3
• 235000010445 lecithin Nutrition 0.000 description 3
• 229940067606 lecithin Drugs 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 230000001394 metastastic effect Effects 0.000 description 3
• 206010061289 metastatic neoplasm Diseases 0.000 description 3
• 125000001624 naphthyl group Chemical group 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 239000004633 polyglycolic acid Substances 0.000 description 3
• 229920005862 polyol Polymers 0.000 description 3
• 150000003077 polyols Chemical class 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 230000002035 prolonged effect Effects 0.000 description 3
• 230000005855 radiation Effects 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 229930195734 saturated hydrocarbon Natural products 0.000 description 3
• 230000008054 signal transmission Effects 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 125000001424 substituent group Chemical group 0.000 description 3
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 238000011269 treatment regimen Methods 0.000 description 3
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
• 206010046766 uterine cancer Diseases 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• 125000004455 (C1-C3) alkylthio group Chemical group 0.000 description 2
• 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 2
• 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 2
• 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 2
• BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
• JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 2
• 206010069754 Acquired gene mutation Diseases 0.000 description 2
• 206010000830 Acute leukaemia Diseases 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• 206010005949 Bone cancer Diseases 0.000 description 2
• 208000018084 Bone neoplasm Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 206010006143 Brain stem glioma Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 108010069514 Cyclic Peptides Proteins 0.000 description 2
• 102000001189 Cyclic Peptides Human genes 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
• 208000017604 Hodgkin disease Diseases 0.000 description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
• 241000701806 Human papillomavirus Species 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• 206010052178 Lymphocytic lymphoma Diseases 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 2
• 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 2
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• 235000009421 Myristica fragrans Nutrition 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 206010034299 Penile cancer Diseases 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
• 201000005746 Pituitary adenoma Diseases 0.000 description 2
• 206010061538 Pituitary tumour benign Diseases 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 208000000453 Skin Neoplasms Diseases 0.000 description 2
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• 108091008874 T cell receptors Proteins 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• 108010017842 Telomerase Proteins 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 102000003425 Tyrosinase Human genes 0.000 description 2
• 108060008724 Tyrosinase Proteins 0.000 description 2
• 201000003761 Vaginal carcinoma Diseases 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• 239000000370 acceptor Substances 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 230000003044 adaptive effect Effects 0.000 description 2
• 230000002730 additional effect Effects 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
• 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 2
• 125000003282 alkyl amino group Chemical group 0.000 description 2
• 125000004414 alkyl thio group Chemical group 0.000 description 2
• 230000000735 allogeneic effect Effects 0.000 description 2
• 230000006229 amino acid addition Effects 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 239000004037 angiogenesis inhibitor Substances 0.000 description 2
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 230000000845 anti-microbial effect Effects 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 125000005100 aryl amino carbonyl group Chemical group 0.000 description 2
• 125000004658 aryl carbonyl amino group Chemical group 0.000 description 2
• 125000005129 aryl carbonyl group Chemical group 0.000 description 2
• 125000005135 aryl sulfinyl group Chemical group 0.000 description 2
• 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 2
• 125000005164 aryl thioalkyl group Chemical group 0.000 description 2
• 239000010425 asbestos Substances 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 229920002988 biodegradable polymer Polymers 0.000 description 2
• 239000004621 biodegradable polymer Substances 0.000 description 2
• 125000006267 biphenyl group Chemical group 0.000 description 2
• 238000010322 bone marrow transplantation Methods 0.000 description 2
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 150000001721 carbon Chemical group 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 125000005518 carboxamido group Chemical group 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000012876 carrier material Substances 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 239000002458 cell surface marker Substances 0.000 description 2
• 229940030156 cell vaccine Drugs 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 208000025997 central nervous system neoplasm Diseases 0.000 description 2
• 208000019065 cervical carcinoma Diseases 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• FLASNYPZGWUPSU-SICDJOISSA-N chitosan Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H](O[C@@H](O[C@@H]2[C@H](O[C@@H](O)[C@H](N)[C@H]2O)CO)[C@H](N)[C@H]1O)CO)NC(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1N FLASNYPZGWUPSU-SICDJOISSA-N 0.000 description 2
• 229960004926 chlorobutanol Drugs 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 208000024207 chronic leukemia Diseases 0.000 description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 239000007891 compressed tablet Substances 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 229920001577 copolymer Polymers 0.000 description 2
• 239000006184 cosolvent Substances 0.000 description 2
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 230000035614 depigmentation Effects 0.000 description 2
• 230000035418 detection of UV Effects 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 231100000507 endocrine disrupting Toxicity 0.000 description 2
• 210000000750 endocrine system Anatomy 0.000 description 2
• 201000003914 endometrial carcinoma Diseases 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 201000001343 fallopian tube carcinoma Diseases 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 238000010579 first pass effect Methods 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 235000019634 flavors Nutrition 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 238000007429 general method Methods 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 125000004438 haloalkoxy group Chemical group 0.000 description 2
• 125000005114 heteroarylalkoxy group Chemical group 0.000 description 2
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
• 125000005368 heteroarylthio group Chemical group 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 150000002430 hydrocarbons Chemical group 0.000 description 2
• 210000003405 ileum Anatomy 0.000 description 2
• 230000008004 immune attack Effects 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 230000000415 inactivating effect Effects 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 210000004347 intestinal mucosa Anatomy 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 239000001115 mace Substances 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 208000026037 malignant tumor of neck Diseases 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 210000002752 melanocyte Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 208000021039 metastatic melanoma Diseases 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 2
• 239000004530 micro-emulsion Substances 0.000 description 2
• 244000000010 microbial pathogen Species 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 229960003301 nivolumab Drugs 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 125000004043 oxo group Chemical group O=* 0.000 description 2
• 239000001301 oxygen Chemical group 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 239000003182 parenteral nutrition solution Substances 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000000149 penetrating effect Effects 0.000 description 2
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
• 210000004214 philadelphia chromosome Anatomy 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 208000021310 pituitary gland adenoma Diseases 0.000 description 2
• 229920000747 poly(lactic acid) Polymers 0.000 description 2
• 239000004626 polylactic acid Substances 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 125000004076 pyridyl group Chemical group 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 201000007444 renal pelvis carcinoma Diseases 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• 229910052895 riebeckite Inorganic materials 0.000 description 2
• 235000002020 sage Nutrition 0.000 description 2
• 201000000849 skin cancer Diseases 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
• 235000010234 sodium benzoate Nutrition 0.000 description 2
• 239000004299 sodium benzoate Substances 0.000 description 2
• 235000010265 sodium sulphite Nutrition 0.000 description 2
• 230000037439 somatic mutation Effects 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 206010041823 squamous cell carcinoma Diseases 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000011593 sulfur Chemical group 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 238000001308 synthesis method Methods 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 229940037128 systemic glucocorticoids Drugs 0.000 description 2
• 210000003411 telomere Anatomy 0.000 description 2
• 230000004797 therapeutic response Effects 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 150000003573 thiols Chemical class 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 239000002691 unilamellar liposome Substances 0.000 description 2
• 210000000626 ureter Anatomy 0.000 description 2
• 201000011294 ureter cancer Diseases 0.000 description 2
• 201000000360 urethra cancer Diseases 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 229910052720 vanadium Inorganic materials 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 208000013013 vulvar carcinoma Diseases 0.000 description 2
• QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
• XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• CRYXXTXWUCPIMU-WNQIDUERSA-N (2s)-2-aminobutanediamide;phenol Chemical compound OC1=CC=CC=C1.NC(=O)[C@@H](N)CC(N)=O CRYXXTXWUCPIMU-WNQIDUERSA-N 0.000 description 1
• OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
• MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
• AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 1
• PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
• GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
• 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical group CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
• MCNQUWLLXZZZAC-UHFFFAOYSA-N 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-piperidin-1-ylpyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl MCNQUWLLXZZZAC-UHFFFAOYSA-N 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• PZBQVZFITSVHAW-UHFFFAOYSA-N 5-chloro-2h-benzotriazole Chemical compound C1=C(Cl)C=CC2=NNN=C21 PZBQVZFITSVHAW-UHFFFAOYSA-N 0.000 description 1
• 102100038776 ADP-ribosylation factor-related protein 1 Human genes 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 241000023308 Acca Species 0.000 description 1
• 208000000819 Adrenocortical Hyperfunction Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
• 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
• 241000224489 Amoeba Species 0.000 description 1
• 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
• 241000238421 Arthropoda Species 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 241000193738 Bacillus anthracis Species 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 208000003508 Botulism Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 101150050673 CHK1 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 241000938605 Crocodylia Species 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
• 241000725619 Dengue virus Species 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 101000633756 Echis pyramidum leakeyi Snaclec 4 Proteins 0.000 description 1
• 241001466953 Echovirus Species 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000709661 Enterovirus Species 0.000 description 1
• 241000991587 Enterovirus C Species 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 241000402754 Erythranthe moschata Species 0.000 description 1
• 101100395869 Escherichia coli sta3 gene Proteins 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 241000710831 Flavivirus Species 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 241000224466 Giardia Species 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 229910004373 HOAc Inorganic materials 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000809413 Homo sapiens ADP-ribosylation factor-related protein 1 Proteins 0.000 description 1
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
• 101001109426 Homo sapiens Nitric oxide-associated protein 1 Proteins 0.000 description 1
• 101000654674 Homo sapiens Semaphorin-6A Proteins 0.000 description 1
• 101000837626 Homo sapiens Thyroid hormone receptor alpha Proteins 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 201000006347 Intellectual Disability Diseases 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 241000588748 Klebsiella Species 0.000 description 1
• 150000008575 L-amino acids Chemical class 0.000 description 1
• 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
• QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 241000222722 Leishmania <genus> Species 0.000 description 1
• 206010024238 Leptospirosis Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241000712079 Measles morbillivirus Species 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 241000700560 Molluscum contagiosum virus Species 0.000 description 1
• 241000711386 Mumps virus Species 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 229910014299 N-Si Inorganic materials 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• 102100022495 Nitric oxide-associated protein 1 Human genes 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 238000012879 PET imaging Methods 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 206010035148 Plague Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000032991 Profound mental retardation Diseases 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 241000588769 Proteus <enterobacteria> Species 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 241000725643 Respiratory syncytial virus Species 0.000 description 1
• 241000606651 Rickettsiales Species 0.000 description 1
• 241000702670 Rotavirus Species 0.000 description 1
• 241000710799 Rubella virus Species 0.000 description 1
• 244000117054 Rungia klossii Species 0.000 description 1
• 235000002492 Rungia klossii Nutrition 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 102100032795 Semaphorin-6A Human genes 0.000 description 1
• 241000607720 Serratia Species 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
• 241000295644 Staphylococcaceae Species 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 230000033540 T cell apoptotic process Effects 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 206010058874 Viraemia Diseases 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 241000607479 Yersinia pestis Species 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 201000005188 adrenal gland cancer Diseases 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 229940087168 alpha tocopherol Drugs 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
• 239000001099 ammonium carbonate Substances 0.000 description 1
• 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 239000000883 anti-obesity agent Substances 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 239000003472 antidiabetic agent Substances 0.000 description 1
• 229940125708 antidiabetic agent Drugs 0.000 description 1
• 230000007503 antigenic stimulation Effects 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 239000003524 antilipemic agent Substances 0.000 description 1
• 230000009876 antimalignant effect Effects 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 229940125710 antiobesity agent Drugs 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 238000011398 antitumor immunotherapy Methods 0.000 description 1
• 238000003782 apoptosis assay Methods 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 159000000032 aromatic acids Chemical class 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
• 210000001815 ascending colon Anatomy 0.000 description 1
• 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
• 229960004168 balsalazide Drugs 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• 235000012216 bentonite Nutrition 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical group C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 238000012742 biochemical analysis Methods 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 229960004395 bleomycin sulfate Drugs 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 235000011132 calcium sulphate Nutrition 0.000 description 1
• 125000001589 carboacyl group Chemical group 0.000 description 1
• 150000003857 carboxamides Chemical group 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 229940105329 carboxymethylcellulose Drugs 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 229940028617 conventional vaccine Drugs 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 229960001305 cysteine hydrochloride Drugs 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 101150047356 dec-1 gene Proteins 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 125000004663 dialkyl amino group Chemical group 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 150000001991 dicarboxylic acids Chemical class 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 208000001848 dysentery Diseases 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 229950009760 epratuzumab Drugs 0.000 description 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
• 238000012921 fluorescence analysis Methods 0.000 description 1
• 230000004907 flux Effects 0.000 description 1
• 229940014144 folate Drugs 0.000 description 1
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 244000053095 fungal pathogen Species 0.000 description 1
• 201000007487 gallbladder carcinoma Diseases 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000003163 gonadal steroid hormone Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
• 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 description 1
• 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 102000043321 human CTLA4 Human genes 0.000 description 1
• 238000011577 humanized mouse model Methods 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 150000002433 hydrophilic molecules Chemical class 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 239000012216 imaging agent Substances 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000008629 immune suppression Effects 0.000 description 1
• 239000003022 immunostimulating agent Substances 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• 238000000111 isothermal titration calorimetry Methods 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 238000000670 ligand binding assay Methods 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 1
• 238000005710 macrocyclization reaction Methods 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 150000008146 mannosides Chemical class 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000003071 memory t lymphocyte Anatomy 0.000 description 1
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
• 229960004963 mesalazine Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 238000001471 micro-filtration Methods 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 210000000066 myeloid cell Anatomy 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 150000007523 nucleic acids Chemical group 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
• 229960004110 olsalazine Drugs 0.000 description 1
• 239000007935 oral tablet Substances 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 150000002905 orthoesters Chemical class 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
• LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
• 101710135378 pH 6 antigen Proteins 0.000 description 1
• 239000003002 pH adjusting agent Substances 0.000 description 1
• 235000019629 palatability Nutrition 0.000 description 1
• 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000013618 particulate matter Substances 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 229960002621 pembrolizumab Drugs 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 229940023041 peptide vaccine Drugs 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 150000008105 phosphatidylcholines Chemical class 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920001610 polycaprolactone Polymers 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 229920000307 polymer substrate Polymers 0.000 description 1
• 239000002952 polymeric resin Substances 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000005522 programmed cell death Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 239000000473 propyl gallate Substances 0.000 description 1
• 235000010388 propyl gallate Nutrition 0.000 description 1
• 229940075579 propyl gallate Drugs 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
• 201000007094 prostatitis Diseases 0.000 description 1
• 239000003223 protective agent Substances 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 231100000336 radiotoxic Toxicity 0.000 description 1
• 230000001690 radiotoxic effect Effects 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 150000003873 salicylate salts Chemical class 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000007086 side reaction Methods 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 201000002314 small intestine cancer Diseases 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 229940100996 sodium bisulfate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 229940001482 sodium sulfite Drugs 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000012414 sterilization procedure Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 229960001940 sulfasalazine Drugs 0.000 description 1
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 229920003002 synthetic resin Polymers 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
• 229940124598 therapeutic candidate Drugs 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 229940021747 therapeutic vaccine Drugs 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
• 229960000984 tocofersolan Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 229960005267 tositumomab Drugs 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000759 toxicological effect Toxicity 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000009966 trimming Methods 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 235000012141 vanillin Nutrition 0.000 description 1
• MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
• FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• CZPRKINNVBONSF-UHFFFAOYSA-M zinc;dioxido(oxo)phosphanium Chemical compound [Zn+2].[O-][P+]([O-])=O CZPRKINNVBONSF-UHFFFAOYSA-M 0.000 description 1
• 239000002076 α-tocopherol Substances 0.000 description 1
• 235000004835 α-tocopherol Nutrition 0.000 description 1
• 229930195724 β-lactose Natural products 0.000 description 1